These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 27492571)

  • 1. Early U.S. Experience Following FDA Approval of the ABBOTT Vascular Bioresorbable Vascular Scaffold: Optimal Deployment Technique Using High Resolution Coronary Artery Imaging.
    Rizik DG; Padaliya BB
    J Interv Cardiol; 2016 Oct; 29(5):546-548. PubMed ID: 27492571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First US experience following FDA approval of the ABBOTT vascular bioresorbable vascular scaffold for the treatment of coronary artery disease.
    Rizik DG; Shah MG; Burke RF
    Catheter Cardiovasc Interv; 2016 Nov; 88(6):899-901. PubMed ID: 27545489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of the 2016 U.S. Food and Drug Administration Circulatory System Devices Advisory Panel Meeting on the Absorb Bioresorbable Vascular Scaffold System.
    Steinvil A; Rogers T; Torguson R; Waksman R
    JACC Cardiovasc Interv; 2016 Sep; 9(17):1757-64. PubMed ID: 27609249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uptake of Drug-Eluting Bioresorbable Vascular Scaffolds in Clinical Practice: An NCDR Registry to Practice Project.
    Chau KH; Kennedy KF; Messenger JC; Garratt KN; Maddox TM; Yeh RW; Kirtane AJ
    JAMA Cardiol; 2019 Jun; 4(6):564-568. PubMed ID: 31066860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries.
    Tamburino C; Capranzano P; Gori T; Latib A; Lesiak M; Nef H; Caramanno G; Naber C; Mehilli J; Di Mario C; Sabaté M; Münzel T; Colombo A; Araszkiewicz A; Wiebe J; Geraci S; Jensen C; Mattesini A; Brugaletta S; Capodanno D
    JACC Cardiovasc Interv; 2016 Mar; 9(5):440-9. PubMed ID: 26875648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioresorbable vascular scaffolds: From patient selection to optimal scaffold implantation; tips and tricks to minimize device failure.
    Tanaka A; Jabbour RJ; Latib A; Colombo A
    Catheter Cardiovasc Interv; 2016 Nov; 88(S1):10-20. PubMed ID: 27797460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioresorbable vascular scaffolds for the treatment of coronary artery disease: what have we learned from randomized-controlled clinical trials?
    Rizik DG; Hermiller JB; Simonton CA; Klassen KJ; Kereiakes DJ
    Coron Artery Dis; 2017 Jan; 28(1):77-89. PubMed ID: 27561169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds.
    Puricel S; Arroyo D; Corpataux N; Baeriswyl G; Lehmann S; Kallinikou Z; Muller O; Allard L; Stauffer JC; Togni M; Goy JJ; Cook S
    J Am Coll Cardiol; 2015 Mar; 65(8):791-801. PubMed ID: 25720622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioresorbable vascular scaffold collapse causes subacute thrombosis.
    Ruiz-Salmerón RJ; Pereira S; de Araujo D
    J Invasive Cardiol; 2014 Jul; 26(7):E98-9. PubMed ID: 24993999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coronary artery perforation at the level of two-overlapping bioresorbable vascular scaffolds: The importance of vessel sizing and scaffold thickness.
    Pichette M; Chevalier F; Généreux P
    Catheter Cardiovasc Interv; 2015 Oct; 86(4):686-91. PubMed ID: 26122768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-scaffold restenosis in a previous left main bifurcation lesion treated with bioresorbable scaffold v-stenting.
    Miyazaki T; Panoulas VF; Sato K; Kawamoto H; Naganuma T; Latib A; Colombo A
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt A):e7-e10. PubMed ID: 25499306
    [No Abstract]   [Full Text] [Related]  

  • 12. Initial experience of percutaneous coronary intervention in bifurcations with bioresorbable vascular scaffolds using different techniques--insights from optical coherence tomography.
    Attizzani GF; Ohno Y; Capranzano P; La Manna A; Francaviglia B; Grasso C; Sgroi C; Tamburino C; Longo G; Fujino Y; Capodanno D; Tamburino C
    Int J Cardiol; 2013 Dec; 170(2):e33-5. PubMed ID: 24210418
    [No Abstract]   [Full Text] [Related]  

  • 13. Mid-term clinical outcomes of ABSORB bioresorbable vascular scaffold versus everolimus-eluting stent for coronary bifurcation lesions.
    Naganuma T; Kawamoto H; Panoulas VF; Latib A; Tanaka A; Mitomo S; Ruparelia N; Jabbour RJ; Chieffo A; Carlino M; Montorfano M; Colombo A
    Int J Cardiol; 2017 Nov; 246():26-31. PubMed ID: 28867010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial.
    Onuma Y; Dudek D; Thuesen L; Webster M; Nieman K; Garcia-Garcia HM; Ormiston JA; Serruys PW
    JACC Cardiovasc Interv; 2013 Oct; 6(10):999-1009. PubMed ID: 24156961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioresorbable vascular scaffolds in left main coronary artery disease.
    Everaert B; Capranzano P; Tamburino C; Seth A; van Geuns RJ
    EuroIntervention; 2015; 11 Suppl V():V135-8. PubMed ID: 25983148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No more metallic cages: an attractive hybrid strategy with bioresorbable vascular scaffold and drug-eluting balloon for diffuse or tandem lesions in the same vessel.
    Naganuma T; Latib A; Ielasi A; Panoulas VF; Sato K; Miyazaki T; Colombo A
    Int J Cardiol; 2014 Apr; 172(3):618-9. PubMed ID: 24495653
    [No Abstract]   [Full Text] [Related]  

  • 17. Follow-up of coronary artery patency after implantation of bioresorbable coronary scaffolds: The emerging role of magnetic coronary artery imaging.
    Zuin M; Rigatelli G; Scaranello F; Rinuncini M; Picariello C; D'Elia K; Fejzo M; Roncon L
    Cardiovasc Revasc Med; 2017; 18(5):369-373. PubMed ID: 28254259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of everolimus-eluting bioresorbable vascular scaffolds versus durable polymer everolimus-eluting metallic stents assessed at 1-year follow-up: A systematic review and meta-analysis of studies.
    Mukete BN; van der Heijden LC; Tandjung K; Baydoun H; Yadav K; Saleh QA; Doggen CJ; Abi Rafeh N; Le Jemtel TH; von Birgelen C
    Int J Cardiol; 2016 Oct; 221():1087-94. PubMed ID: 27448538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bioresorbable Vascular Scaffold: A Focused Review on Development and Preclinical Studies].
    Ke L; Huang Y; Liu L; Duan X; Feng X; Wang C
    Zhongguo Yi Liao Qi Xie Za Zhi; 2018 Feb; 42(2):115-118. PubMed ID: 29845812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioresorbable vascular scaffold thrombosis in a consecutive cohort of 550 patients.
    Tröbs M; Achenbach S; Röther J; Klinghammer L; Schlundt C
    Catheter Cardiovasc Interv; 2016 Nov; 88(6):872-880. PubMed ID: 27142643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.